These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 30977014)

  • 1. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
    Kano M; Hayano K; Hayashi H; Hanari N; Gunji H; Toyozumi T; Murakami K; Uesato M; Ota S; Matsubara H
    Ann Surg Oncol; 2019 Jun; 26(6):1805-1813. PubMed ID: 30977014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
    Kosaka T; Akiyama H; Miyamoto H; Sato S; Tanaka Y; Sato K; Kunisaki C; Endo I
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1047-1055. PubMed ID: 30911769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
    Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002).
    Fujitani K; Tamura S; Kimura Y; Matsuyama J; Imamura H; Yamamoto K; Fujita J; Iijima S; Ueda S; Kurokawa Y; Shimokawa T; Satoh T;
    Gastric Cancer; 2020 May; 23(3):520-530. PubMed ID: 31667688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03.
    Okabe H; Hata H; Ueda S; Zaima M; Tokuka A; Yoshimura T; Ota S; Kinjo Y; Yoshimura K; Sakai Y;
    J Surg Oncol; 2016 Jan; 113(1):36-41. PubMed ID: 26604064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
    Wang Y; Cheng X; Cui YH; Hou J; Ji Y; Sun YH; Shen ZB; Liu FL; Liu TS
    BMC Cancer; 2018 Jun; 18(1):702. PubMed ID: 29954358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial.
    Lee CK; Jung M; Kim HS; Jung I; Shin DB; Kang SY; Zang DY; Kim KH; Lee MH; Kim BS; Lee KH; Cheong JH; Hyung WJ; Noh SH; Chung HC; Rha SY
    Cancer Res Treat; 2019 Jan; 51(1):1-11. PubMed ID: 29397659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer.
    Kochi M; Fujii M; Kanamori N; Kaiga T; Takahashi T; Kobayashi M; Takayama T
    J Cancer Res Clin Oncol; 2006 Dec; 132(12):781-5. PubMed ID: 16804723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.
    Endo S; Terazawa T; Goto M; Tanaka R; Kato T; Fujitani K; Kawakami H; Sakai D; Kurokawa Y; Tsujinaka T; Shimokawa T; Satoh T
    BMC Cancer; 2022 Jul; 22(1):811. PubMed ID: 35870893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 11. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
    Kang YK; Yook JH; Park YK; Lee JS; Kim YW; Kim JY; Ryu MH; Rha SY; Chung IJ; Kim IH; Oh SC; Park YS; Son T; Jung MR; Heo MH; Kim HK; Park C; Yoo CH; Choi JH; Zang DY; Jang YJ; Sul JY; Kim JG; Kim BS; Beom SH; Cho SH; Ryu SW; Kook MC; Ryoo BY; Kim HK; Yoo MW; Lee NS; Lee SH; Kim G; Lee Y; Lee JH; Noh SH
    J Clin Oncol; 2021 Sep; 39(26):2903-2913. PubMed ID: 34133211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
    Kang YK; Kim HD; Yook JH; Park YK; Lee JS; Kim YW; Kim JY; Ryu MH; Rha SY; Chung IJ; Kim IH; Oh SC; Park YS; Cheong JH; Jeong O; Heo MH; Kim HK; Park C; Yoo CH; Kang SY; Zang DY; Jang YJ; Sul JY; Kim JG; Kim BS; Beom SH; Hwang JE; Ryu SW; Kook MC; Ryoo BY; Kim H; Yoo MW; Lee NS; Lee SH; Noh SH
    J Clin Oncol; 2024 Sep; 42(25):2961-2965. PubMed ID: 38996201
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial.
    Hosoda K; Azuma M; Katada C; Moriya H; Mieno H; Ishido K; Ema A; Ushiku H; Wada T; Washio M; Watanabe A; Higuchi K; Tanabe S; Koizumi W; Watanabe M; Yamashita K
    Gastric Cancer; 2019 May; 22(3):598-606. PubMed ID: 30284080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer.
    Sasaki K; Onodera S; Otsuka K; Satomura H; Kurayama E; Kubo T; Takahashi M; Ito J; Nakajima M; Yamaguchi S; Miyachi K; Kato H
    Med Oncol; 2017 Aug; 34(8):139. PubMed ID: 28707042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study.
    Kim IH; Park SS; Lee CM; Kim MC; Kwon IK; Min JS; Kim HI; Lee HH; Lee SI; Chae H
    Ann Surg Oncol; 2018 May; 25(5):1176-1183. PubMed ID: 29450755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of docetaxel and S-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer.
    Oki E; Emi Y; Kusumoto T; Sakaguchi Y; Yamamoto M; Sadanaga N; Shimokawa M; Yamanaka T; Saeki H; Morita M; Takahashi I; Hirabayashi N; Sakai K; Orita H; Aishima S; Kakeji Y; Yamaguchi K; Yoshida K; Baba H; Maehara Y
    Ann Surg Oncol; 2014 Jul; 21(7):2340-6. PubMed ID: 24604583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy.
    Fujitani K; Tamura S; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Shimokawa T; Tsujinaka T; Furukawa H
    Gastric Cancer; 2014 Apr; 17(2):348-53. PubMed ID: 23736741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
    Nakamura Y; Yamanaka T; Chin K; Cho H; Katai H; Terashima M; Misawa K; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Bando H; Kawashima Y; Fukunaga T; Gotoh M; Ishibashi T; Shitara K
    Ann Surg Oncol; 2019 Feb; 26(2):465-472. PubMed ID: 30456678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.
    Yoshida K; Kodera Y; Kochi M; Ichikawa W; Kakeji Y; Sano T; Nagao N; Takahashi M; Takagane A; Watanabe T; Kaji M; Okitsu H; Nomura T; Matsui T; Yoshikawa T; Matsuyama J; Yamada M; Ito S; Takeuchi M; Fujii M
    J Clin Oncol; 2019 May; 37(15):1296-1304. PubMed ID: 30925125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
    Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
    BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.